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Abstract
Introduction: Umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) are self-renewing multipotent
progenitors with the potential to differentiate into multiple lineages of mesoderm, in addition to generating
ectodermal and endodermal lineages by crossing the germline barrier. In the present study we have investigated
the ability of UCB-MSCs to generate neurons, since we were able to observe varying degrees of neuronal
differentiation from a few batches of UCB-MSCs with very simple neuronal induction protocols whereas other
batches required extensive exposure to combination of growth factors in a stepwise protocol. Our hypothesis was
therefore that the human UCB-MSCs would contain multiple types of progenitors with varying neurogenic
potential and that the ratio of the progenitors with high and low neurogenic potentials varies in different batches
of UCB.
Methods: In total we collected 45 UCB samples, nine of which generated MSCs that were further expanded and
characterized using immunofluorescence, fluorescence-activated cell sorting and RT-PCR analysis. The neuronal
differentiation potential of the UCB-MSCs was analyzed with exposure to combination of growth factors.
Results: We could identify two different populations of progenitors within the UCB-MSCs. One population
represented progenitors with innate neurogenic potential that initially express pluripotent stem cell markers such
as Oct4, Nanog, Sox2, ABCG2 and neuro-ectodermal marker nestin and are capable of expanding and
differentiating into neurons with exposure to simple neuronal induction conditions. The remaining population of
cells, typically expressing MSC markers, requires extensive exposure to a combination of growth factors to
transdifferentiate into neurons. Interesting to note was that both of these cell populations were positive for CD29
and CD105, indicating their MSC lineage, but showed prominent difference in their neurogenic potential.
Conclusion: Our results suggest that the expanded UCB-derived MSCs harbor a small unique population of cells
that express pluripotent stem cell markers along with MSC markers and possess an inherent neurogenic potential.
These pluripotent progenitors later generate cells expressing neural progenitor markers and are responsible for the
instantaneous neuronal differentiation; the ratio of these pluripotent marker expressing cells in a batch determines
the innate neurogenic potential.
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Introduction
Umbilical cord blood (UCB) is considered one of the
most abundant sources of non-embryonic stem cells [1].
The collection of mesenchymal stem cells (MSCs) from
UCB that is discarded at the time of birth is an easier,
less expensive and non-invasive method than collecting
MSCs from bone marrow aspirates [2]. These MSCs
attract special interest due to these specific advantages
over embryonic and adult stem cell counterparts, since
there are also no ethical issues associated with UCB.
Another important characteristic of UCB-MSCs is that
they are less immunogenic, and therefore do not elicit
the proliferative response of allogeneic lymphocytes in
vitro [3]. UCB-MSCs expanded in vitro also retain low
immunogenicity and an immunomodulatory effect.
Moreover, cells derived from the UCB elicit a lower inci-
dence of graft rejection and post-transplant infections
compared with other sources [4].
Considering these facts, UCB-derived MSCs can there-
fore be effectively utilized for therapeutic applications of
various diseases. These applications include cell-based
therapy to replenish degenerated neurons, cardiac cells,
muscle cells, chondrocytes, and so forth. However, the
potential application of these cells for various purposes
requires extensive characterization, and requires standar-
dization of reproducible differentiation protocols with
ultimate functional characterization of the differentiated
cells. Morphologically, the MSCs are adherent, fibro-
blast-like cells [5] with multipotent differentiation poten-
tial and thus can be induced to differentiate into cells of
multiple lineages such as adipocytes, osteocytes, chon-
drocytes, myocytes, hepatocytes, neurons and astrocytes
[6-10]. Several groups have explored the possibility of
generating functional neurons from UCB-MSCs to use
for various neurodegenerative diseases. Administration of
human umbilical cord blood (hUCB)-MSCs was found to
be feasible treatment for brain injuries such as stroke and
other degenerative disorders [11,12]. Transplanting
hUCB-MSCs in spinal cord injury animal models has
shown significant improvement in neurological function
[13].
Even though the hUCB-derived cells have been shown
to differentiate into different lineages [14], a high potential
for neuronal differentiation has been shown with extensive
exposure to multiple combinations of growth factors
[15-18]. In vitro treatment with b-mercaptoethanol and
retinoic acid resulted in a very drastic difference in cellular
morphology of MSCs from fibroblastic to spindle-shaped
with elongated processes resembling a neuronal phenotype
[19]. Previous reports have shown that hUCB-MSCs can
be transdifferentiated into neuronal lineage by treating
with nerve growth factor and retinoic acid. This multi-
lineage differentiation capacity, the expression of neural
properties and overlapping genetic programs for hemato-
poiesis and neuropoiesis [20] suggest that hUCB cells may
have the ability to transdifferentiate in to neural cells. Few
reports have shown that UCB-derived progenitors can
express Oct3/4, Sox2, Nanog and Rex1, which are pluripo-
tent/multi-lineage markers and could possibly differentiate
into multiple lineages [21-23]. Convincing evidence there-
fore appears to show that hUCB-MSCs can be used as a
good source for generating neurons, but there exists a
considerable difference in the neurogenic potential of dif-
ferent batches of MSCs obtained from UCB.
The multi-lineage differentiation capacity and an
inherent neuronal differentiation potential observed in a
few batches made us characterize the hUCB-derived
cells in detail with respect to neurogenic potential, since
evaluating the neurogenic potential of hUCB-MSCs iso-
lated for any possible cell replacement therapeutic appli-
cations is really important. Our results have in fact
shown that the hUCB-MSCs varied in their neurogenic
differentiation potential between samples, with a few
showing the presence of a unique population of cells
with inherent neurogenic potential even though they
phenotypically express MSC markers.
Materials and methods
Umbilical cord blood MSC isolation and culture
UCB samples were collected from 45 full-term delivery
cases with previous consent from the mothers according
to the Institute’s human ethical committee guidelines.
The UCB samples collected were coded as hUCB-MSC
SCB1 to SCB45. The samples used for mononuclear cell
(MNC) isolation alone were coded as hUCB MNC01 to
MNC03. Clinical parameters for the mother and baby
were also noted for latter correlation with the yield of
MSCs. The parameters recorded were the gestation per-
iod, UCB blood volume collected, and body weight of
the baby (see Table S1 in Additional file 1).
UCB units were collected into 50 ml sterile tubes con-
taining anticoagulant (acid citrate dextrose solution). All
samples were processed within 4 to 6 hours from collec-
tion. Blood was diluted in 1× PBS in a 1:1 ratio and
MNCs were isolated by density gradient centrifugation
using Percoll gradient (GE Life Sciences, Piscataway, NJ,
USA) [24]. MNCs obtained after the Percoll gradient
separation were washed twice in 1× PBS and resus-
pended with CD34 antibody-conjugated beads (Miltenyi
Biotech, Cologne, Germany) and were incubated for 30
minutes at 4°C followed by selective depletion of CD34-
positive cells. The CD34-depleted population was col-
lected and further resuspended in proliferation medium
consisting of Iscove’s modified Dulbecco’s medium
(IMDM) (Gibco, Life Technologies, Carlsbad, CA, USA)
with 20% FBS (Hyclone Laboratories, Logan, UT, USA),
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20 ng/ml fibroblast growth factor (FGF)-2 (Chemicon,
Millipore, Billerica, MA, USA), 2 mg/ml heparin (Sigma,
St.Louis, MO, USA), 1% penicillin/streptomycin (Gibco)
and was plated in T25 flasks at a density of 5 × 106
cells/ml. After 24 hours of incubation at 37°C with 5%
CO2, the nonadherent cells were washed off and the
attached cells were expanded further with medium
being replenished every alternate day. All differentiation
protocols were carried out with MSCs between passages
3 and 4. Immortalized hUCB-derived MSC line RCB
2080 procured from RIKEN (Tsukuba, Ibaraki, Japan)
was cultured in the same medium and was used as a
control. Cells were passaged upon reaching 70 to 80%
confluence using 0.05% Trypsin-ethylenediamine tetraa-
cetate (Gibco) and were replated or cryopreserved for
subsequent experiments.
Immunophenotyping of human umbilical cord blood
MSCs
Characterization of hUCB-MSCs was carried out by
immunophenotyping using both MSC-positive and MSC-
negative surface markers. Briefly, 60 to 80% confluent
flasks of expanded MSCs were trypsinized, followed by
washing with 1× PBS and fixed in 4% paraformaldehyde
for 15 minutes at 4°C. Cells were then incubated with
FITC/PE-conjugated CD73 (1:100; BD Pharmingen, San
diego, CA, USA), CD44 (1:100; BD Pharmingen), CD45
(1:100; BD Pharmingen), CD105 (1:100; BD Pharmingen)
and CD29 (1:100; BD Pharmingen) primary antibodies in
the dark at 4°C for 1 hour and finally resuspended in 1×
PBS containing 3% BSA for fluorescence-activated cell
sorting analysis. To avoid nonspecificity and background
staining, appropriate isotype secondary antibody controls
(mouse IgG-Att488 and mouse IgG-PE) and cell-only
controls were used. A total of 10,000 events were analyzed
using a BD FACS Aria Flow Cytometer (BD Biosciences,
San jos, CA, USA).
Immunofluorescence analysis
For immunostaining, hUCB-MSCs were grown on cover-
slips in 24-well plates for 48 hours for proliferation and
for 5 to 12 days for differentiation. Immunofluorescence
analysis of cells was carried out as described previously
[25]. Briefly, cells were fixed in 4% paraformaldehyde
(Sigma), followed by blocking in 0.4% blocking solution
for detecting nuclear antigens,0.2% blocking solution for
cytoplasmic antigens and 0.1% blocking solution for sur-
face antigens. The cells were then incubated with the
following primary antibodies against b-III-tubulin (1:200;
Chemicon), nestin (1:50; Developmental Studies Hybri-
doma Bank, University of Iowa, Iowa City, Iowa, USA), 5-
bromo-2-deoxyuridine (BrdU) (1:100; Abcam Cambridge,
UK), Sox2 (1:500; Abcam), Musashi (1:100; Chemicon),
Vimentin (1:100; Developmental Studies Hybridoma
Bank), CD105 (1:100; BD Pharmingen), CD29 (1:100; BD
Pharmingen), CD44 (1:100; BD Pharmingen), CD73
(1:100; BD Pharmingen) and CD45 (1:100; BD Pharmin-
gen). This incubation was followed by nuclear staining
with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma).
Cells were examined for epifluorescence following
incubation with appropriate secondary antibody conju-
gated to Cy3/FITC (1:400; Jackson Immunoresearch, Phi-
ladelphia, PA, USA) in an upright fluorescent microscope
(Olympus BX61, Olympus, Tokyo, Japan) and images
were captured using a cooled CCD camera (Andor 885;
Andor Technologies, Belfast, UK). For quantification of
the percentage of cells expressing a specific marker in
any given experiment, the number of positive cells of the
whole population was determined relative to the total
number of 4’,6-diamidino-2-phenylindole-stained cells.
The specificity of nestin, Sox2 and Musashi antibodies
were determined using embryonic day 14 cortical neuro-
nal cultures (see Figure S1 in Additional file 2); similarly,
nonspecific binding of flurochrome-conjugated second-
ary antibodies was excluded by incubating the secondary
antibody alone with MSC cultures (see Figure S2 in
Additional file 3).
5-Bromo-2-deoxyuridine incorporation and proliferation
assay
BrdU incorporation for proliferation analysis was per-
formed as previously described [26]. Briefly, 10 μM BrdU
(Sigma) was added along with culture medium for prolif-
eration assays. Cells were fixed in 4% paraformaldehyde
at 4°C for 15 minutes followed by treatment with 2 N
HCl for 45 minutes and with 0.1 M boric acid for 10
minutes to expose the DNA for BrdU immunostaining.
The treated cells were incubated with primary anti-BrdU
antibody (1:100; Abcam) overnight at 4°C followed by
1 hour of incubation at room temperature with goat anti-
rat FITC-conjugated secondary antibody.
RT-PCR analysis
RT-PCR analysis was carried out as previously described
[25]. Briefly, total RNA was isolated from unexpanded
hUCB-MNCs, proliferating UCB-MSCs and differentiating
UCB-MSCs using an RNA isolation kit (Qiagen RNAeasy
kit, Qiagen, Valencia, CA, USA). Then ~2 μg RNA was
transcribed into cDNA using random hexamers (Promega
Corporation, Madison, WI, USA) and Superscript RT
(Invitrogen, Carlsbad, CA, USA). Specific transcripts were
amplified with gene-specific forward and reverse primers
(see Table S2 in Additional file 4) in a Robocycler Gradi-
ent 96 thermocycler (Stratagene, Stratagene, La Jolla, CA,
USA). The housekeeping gene b-actin was used as control
to normalize the gene-specific expression. PCR products
were separated by gel electrophoresis on 1.8% agarose gel
in 1× Tris-acetate-ethylenediamine tetraacetate buffer and
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visualized by ethidium bromide staining, and images were
captured using a Biorad Gel documentation system.
Neuronal differentiation of human umbilical cord blood
MSCs
We used two different protocols for neuronal differentia-
tion of hUCB-MSCs. The first was a four-step induction
protocol consisting of exposure to a series of growth fac-
tors that push the MSCs towards a neuronal lineage [24].
Briefly, the cells were exposed for 3 days to Step-1 med-
ium consisting of IMDM supplemented with FGF-2
(5 ng/ml), retinoic acid (0.5 μM) and 1 mM 2-mercap-
toethanol, followed by 3 days in Step-2 medium consist-
ing of IMDM supplemented with 1 mM cAMP and 100
μM AsA. The cells were further exposed to Step-3 med-
ium consisting of IMDM supplemented with 10 μM
hydrocortisone and 1 mM cAMP, followed again by
3 days in Step-4 medium consisting of IMDM supple-
mented with 20 ng/ml aFGF, 10 ng/ml Shh, 10 ng/ml
brain-derived neurotrophic factor, 10 ng/ml nerve
growth factor, 25 ng/ml vitronectin, 100 μM AsA, 0.1
mM 3- isobutyl-1-methylxanthine, 10 μM forskolin and
20 nM phorbol myristate acetate. For the second proto-
col involving direct neuronal differentiation, we used
normal neuronal differentiation medium containing neu-
robasal medium supplemented with FGF-2 (10 ng/ml)
and 1% FBS for 5 days.
Statistical analysis
Data from all the experiments are represented as the
mean ± standard deviation of triplicates (n = 3) from
three different experiments. Statistical significance
between groups was calculated by independent Student
t test assuming equal variance. P <0.05 was considered
statistically significant.
Results
Our initial interest was to isolate MSCs from UCB and
check their potential to transdifferentiate into neurons,
but surprisingly we found significant variations between
the isolated MSCs from different batches - this led us to
further characterize these hUCB-MSCs. All of the clinical
parameters analyzed were in correlation with previously
reported optimal condition for blood banking [27]. In
total we collected 45 UCB samples, nine of which gener-
ated MSCs that were further expanded and characterized.
The overall efficiency of MSC isolation from UCB there-
fore appears to be 20%. The majority of these 20% UCBs
had high yield of MSCs and originated from babies with
a higher mean body weight and a decrease in gestation
period. There are previous reports where the increase in
cell yield was reported to correlate with an increase in
baby’s body weight and a decrease in gestational duration
[28,29].
Interestingly, the most viable and expanded hUCB-
MSC cells (hUCB-MSC SCB4) obtained for our study
also matched these criteria (3.87 kg body weight and 36
weeks of gestation), compared with the mean body
weight of 2.81 ± 0.45 kg and a gestation duration of 37.93
± 1.30 weeks. For most of our experiments we used these
MSCs that showed variation in their neurogenic differen-
tiation potential, even though all of them expressed MSC
surface markers. We also used an immortalized hUCB-
MSC cell line (RCB 2080 from RIKEN) as a positive con-
trol to characterize the proliferation and differentiation
potential of the expanded hUCB-MSCs.
Immunophenotyping of expanded human UCB-MSCs
confirms their MSC phenotype
To characterize the expanded hUCB-MSCs, we initially
checked the expression profile of MSC-specific surface
markers such as CD105, CD73, CD29 and CD44. Fluores-
cence-activated cell sorting analysis showed that all of the
expanded hUCB-MSCs were positive for CD29 (88.5 ±
0.11%) and CD105 (87.2 ± 0.29%), although variation in
percentage of CD105 expression was observed in few
batches (Figure 1A to 1F). These results were compared
with those of the immortalized hUCB-MSC cell line,
which was also positive for CD29 (93.0 ± 3.56%) and
CD105 (50.8 ± 5.21%) (Figure 1G). The variation in co-
expression of CD29 and CD105 in different batches was
the initial indication that the composition of all the
expanded UCB-MSCs may not be similar even though all
of them showed an adherent, fibroblastic morphology.
Our results also indicated that all of the isolated hUCB-
MSCs and the immortalized hUCB-MSC cell line were
negative for hematopoietic surface markers CD34 and
CD45 (data not shown).
To further confirm the MSC phenotype of the isolated
progenitors, we carried out immunocytochemical analysis
with the abovementioned cell surface markers. Our results
showed that majority of the expanded cells were positive
for CD105, CD29, CD44 and CD73 and were negative for
CD45 (Figure 2A to 2T). The MSC phenotype of these
isolated progenitors was further corroborated with RT-
PCR analysis with MSC-positive markers as mentioned
above and also with Vimentin, another important MSC
marker (Figure 2U).
Unexpanded UCB-derived mononuclear cells express
mesenchymal and pluripotency markers
We had previously observed a very high co-expression of
CD29 (88.5 ± 0.11%) and CD105 (87.2 ± 0.29%) in the
expanded hUCB-MSCs (hUCB-MSC SCB4; Figure 1E, F)
compared with other batches and with the immortalized
hUCB-MSC cell line (Figure 1A, B). We therefore
decided to further characterize these progenitors with
respect to expression of pluripotency markers.
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Figure 1 Immunophenotyping of control RCB 2080 cell line and expanded human UCB-MSCs. (A) to (F) Adherent human umbilical cord
blood-derived mesenchymal stem cells (hUCB-MSCs) and the RCB 2080 cell line were trypsinized at passage number 3 and fluorescence-
activated cell sorting (FACS) analysis was carried out with important MSC surface markers CD105 and CD29. All expanded hUCB-MSCs showed
approximately 94% positivity for CD29 and 47% positivity for CD105. (G) Percentage of MSC-positive surface markers in the control RCB 2080 cell
line and expanded hUCB-MSCs by FACS analysis. Blank histogram represents cells-only control. Data represented as mean ± standard deviation
of triplicates (n = 3) from three different experiments.
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Figure 2 Isolation of human UCB-MSCs and their characterization in comparison with the human UCB-MSC cell line. (A) to (T)
Immunofluorescence analysis of the control mesenchymal stem cells (MSC) cell line RCB 2080 and expanded human umbilical cord blood-derived
(hUCB)-MSCs with MSC-positive surface markers CD105, CD29 and CD73 and MSC-negative surface marker CD45, clearly showing the RCB 2080 hUCB-
MSC cell line as well as the expanded hUCB-MSCs staining positively for MSC-positive markers and negative for MSC-negative marker, confirming the
MSC phenotype. (U) RT-PCR analysis of expanded proliferating hUCB-MSCs with MSC-positive surface markers such as CD29, CD73, CD105, and
Vimentin showing good levels of expression at the mRNA level, also including the control hUCB-MSC cell line RCB 2080.
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RT-PCR analysis of hUCB-MSC SCB4 cells showed a
very high expression level of nestin and Sox2 and moder-
ate expression of Nanog and Oct4, and were negative for
ABCG2, indicating a typical neural progenitor profile
(Figure 3A, C). We also checked for expression of pluripo-
tency markers in hUCB-MSC SCB10 and hUCB-MSC
SCB14, and found that only hUCB-MSC SCB10 have high
expression of nestin and Oct4, whereas hUCB-MSC
SCB14 had a very low expression of nestin and Oct4 com-
pared with hUCB-MSC SCB4 and hUCB-MSC SCB10
(Figure 3D, F). These results clearly show that the expres-
sion of nestin and other pluripotent markers vary in differ-
ent batches of MSCs.
We next compared the expression profile of freshly iso-
lated unexpanded hUCB-MNCs (hUCB MNC01, MNC02
and MNC03; Figure 3A, B, D, E) and found that MNC01
and MNC02 had high expression levels of pluripotency
markers such as ABCG2, Sox2, Nanog and Oct4 but were
negative for nestin. These results were very interesting
since it appears that the MNCs isolated from UCB consists
of progenitors expressing pluripotency markers, which
later expand into phenotypically MSC-like cells expressing
neural progenitor markers. Practically, we were unable to
purify this population of progenitors expressing pluripo-
tency markers from the freshly isolated MNCs since the
percentage of these progenitors were very low. We also
checked for a similar pluripotency/neural progenitor mar-
ker expression profile in the RCB 2080 cell line, and found
that - except for the expression of nestin - all pluripo-
tency/neural progenitor marker expression was low com-
pared with the hUCB-MSC SCB4 and hUCB-MSC SCB10
progenitors (Figure 3A, C, D, F).
From our results it therefore appears that the hUCB-
MSC SCB4 and hUCB-MSC SCB10 progenitors may
have a very high neurogenic differentiation potential
compared with other MSCs. To further confirm the neu-
rogenic potential of hUCB-MSC SCB4 and hUCB-MSC
SCB10 cells, we exposed them to the simple neuronal dif-
ferentiation condition used for embryonic stem cell-
derived neural progenitor differentiation and compared
the expression with that of the RCB 2080 cell line [25].
To our surprise the hUCB-MSC SCB4 cells exposed to
neurobasal medium and FBS (neurobasal + 1% FBS) and
neurobasal + FGF-2 + 1% FBS readily differentiated into
morphologically neuronal-like cells (Figure 3M, N), and
hUCB-MSC SCB10 showed a moderate neuronal diff-
erentiation (Figure 3R) compared with RCB 2080 cells,
which did not show any neuronal differentiation (Figure
3G to 3J). These results therefore confirmed that the
hUCB-MSC SCB4 and hUCB-MSC SCB10 cells were dif-
ferent from the immortalized UCB-MSC cell line RCB
2080 with respect to its neurogenic potential. We further
analyzed other batches of UCB-MSCs to check their
potential to differentiate into neurons, but none of them
showed neurogenic potential similar to hUCB-MSC
SCB4 and hUCB-MSC SCB10.
Percentage of proliferating BrdU+ve/nestin+ve
mesenchymal stem cells varies in different batches of
umbilical cord blood
Knowing that the hUCB-MSC SCB4 cells possess very
high neurogenic potential, we next decided to compare
the expression of neuroectodermal marker nestin in prolif-
erating MSCs of other UCB batches and also with that of
the immortalized RCB 2080 MSC cell line. For this com-
parison, different batches of cells were exposed to BrdU
during expansion and the expression of neural progenitor
marker nestin was analyzed by immunocytochemistry.
Interestingly, the hUCB-MSC SCB4 cells had a very signif-
icantly high (23.33 ± 1.38, P < 0.001; Figure 4I to 4L, Q)
percentage of cells having BrdU incorporation and
co-expressing nestin compared with other batches, even
though these cells showed co-expression of nestin and
BrdU to a lesser extent (hUCB-MSC SCB1 and hUCB-
MSC SCB10; Figure 4E to 4H, M to 4P, Q). The RCB
2080 cell line also showed a minimum number of BrdU+ve
and nestin+ve MSCs (Figure 4A to 4D, Q).
To further confirm whether the progenitors expressing
MSC markers phenotypically are those that also express
neural progenitor markers, we tried to check for co-
localization of both neural progenitor markers along
with MSC surface markers. The comparison was made
between the hUCB-MSC SCB4 and the RCB 2080 UCB-
MSC cell line. Our results showed that majority of the
CD29-expressing cells in hUCB-MSC SCB4 also co-
expressed neural progenitor markers Musashi and Sox2
compared with the RCB 2080 cell line (Figure 5A to
5P). A similar result was also seen with MSCs co-
expressing Vimentin and Musashi. Here, the percentage
of Vimentin+ve Musashi+ve cells was again higher in
hUCB-MSC SCB4 cells compared with the RCB 2080
cell line (Figure 5Q to 5X). These results further con-
firm that indeed there exist progenitors that phenotypi-
cally express MSC markers and also co-express neural
progenitor markers in addition to progenitors positive
for MSC markers alone.
A similar comparison was made with hUCB-MSC
SCB10 cells where we could not find a significant co-
localization of CD29 with Musashi, but were able to
find cells co-localizing CD29 and Sox2 (see Figure S3 in
Additional file 5). hUCB-MSC SCB4 and hUCB-MSC
SCB10 therefore appear to have a higher neurogenic
potential compared with hUCB-MSC SCB1, but with
varying levels. These results confirmed that indeed there
exists variation in the neurogenic potential among dif-
ferent batches of hUCB-MSCs.
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Figure 3 Human UCB-MSCs show expression of pluripotent and neural progenitor markers. (A) RT-PCR analysis shows the presence of
transcripts corresponding to pluripotent as well as neural progenitor markers in freshly isolated human umbilical cord blood-derived (hUCB)
mononuclear cell MNC01 and also in expanded mesenchymal stem cell (hUCB-MSC) SCB4 (lanes 4 and 5). hUCB MNC01 showed a significant level of
expression of pluripotent markers but lacked nestin expression when compared with control RCB 2080 (lane 2), whereas hUCB-MSC SCB4 showed a
higher level of nestin and reduced level of pluripotent marker expression. (B) Comparison of the relative pixel intensity of gene expression in hUCB
MNC01. (C) Comparison of the relative pixel intensity of gene expression in RCB 2080 and hUCB-MSC SCB4. (D) Comparison of pluripotent marker and
neural stem cell marker expression in two more sets of hUCB-MNCs (MNC02 and MNC03) and hUCB-MSCs (hUCB-MSC SCB10 and SCB14), which also
shows a varying pattern of expression corroborating our previous observations that neural stem cell marker expression varies from sample to sample.
(E) Relative pixel intensity of gene expression in hUCB MNC02 and MNC03. (F) Relative pixel intensity of gene expression in hUCB-MSC SCB10 and
hUCB-MSC SCB14. (G) to (R) Treatment of control RCB 2080, hUCB-MSC SCB4 and hUCB-MSC SCB10 cells with neurobasal (NB) medium in
combination with and without 0.5 μm retinoic acid (RA), 1% FBS and 10 ng basic fibroblast growth factor (bFGF). Scale bar = 100 μm.
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Figure 4 Neural progenitor percentage present in isolated human UCB-MSCs varies in different human UCB samples. (A) to (P)
Immunofluorescence analysis with neural progenitor marker nestin and proliferation marker 5-bromo 2-deoxyuridine (BrdU) suggested the
presence of proliferating neural progenitors in human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and the number of
nestin+ve/BrdU+ve cells was different from batches to batches. (Q) Percentage of nestin+ve/BrdU+ve cells in control hUCB-MSC cell line RCB 2080
and other expanded hUCB-MSCs SCB1, SCB4 and SCB10. The control RCB 2080 cell line showed only about 2% nestin+ve/BrdU+ve cells, which
was significantly low when compared with the expanded hUCB-MSCs. hUCB-MSC SCB4 showed a significantly high percentage of nestin+ve/BrdU
+ve cells (~23%), suggesting that these cells are more inclined to neuronal lineage. Another two batches, hUCB-MSC SCB1 and SCB10, also
contained nestin+ve/BrdU+ve cells but the percentage was less compared with the hUCB-MSC SCB4, and at the same time comparatively higher
than the control hUCB-MSC cell line RCB 2080. Data represented as mean ± standard deviation of triplicates (n = 3) from three different
experiments. Scale bar = 100 μm. BF, Bright Field.
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Figure 5 Human UCB-MSC SCB4 express neural progenitor marker without losing their MSC identity. (A) to (H) Expression of neural stem cell
(NSC) marker Musashi was significantly high in human umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) SCB4 and co-expressed with
CD29 when compared with RCB 2080 (I) to (P). Although the RCB 2080 cell line showed the presence of the NSC marker Sox2, the expression was
comparatively high in hUCB-MSC SCB4 and co-localized with CD44. (Q) to (X) Similar co-localization was also seen in hUCB-MSC SCB4 upon Vimentin-
Musashi co-immunostaining, whereas co-localization was very low in control RCB 2080. Scale bar = 100 μm. DAPI, 4’,6-diamidino-2-phenylindole.
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Human UCB-MSCs expressing neural progenitor markers
instantaneously differentiate into neurons upon exposure
to regular neuronal differentiation conditions
Since our previous results proved that the hUCB-MSC
SCB4 cells have an inherent neurogenic potential, we
next subjected them to a previously reported transdiffer-
entiation condition [24]. We also included hUCB-MSC
SCB10 cells since they have also shown higher expression
of the neural progenitor marker nestin (Figure 3C, D).
The MSCs were exposed to four different combinations
of growth factors as described in Materials and methods
(Figure 6A). The differentiation potential of hUCB-MSC
SCB4 and hUCB-MSC SCB10 cells were compared with
that of the RCB 2080 cell line. Our results indicate that
the RCB 2080 cell line could be very effectively transdif-
ferentiated into neurons and stained positive for b-III
tubulin (35.16 ± 8.22; Figure 6B to 6E, N). The percen-
tage of b-III tubulin-positive cells were also significantly
high (P < 0.001) compared with hUCB-MSC SCB4 and
hUCB-MSC SCB10 (15.90 ± 4.28 and 7.41 ± 1.59, respec-
tively; Figure 6F to 6M, N). This was a very interesting
observation since we expected hUCB-MSC SCB4 cells to
generate more neurons compared with the RCB 2080 cell
line. This result could be due to the fact that the RCB
2080 cell line expressing MSC markers alone was
induced to transdifferentiate into neurons by the four-
step induction condition, whereas hUCB-MSC SCB4 and
hUCB-MSC SCB10 contained only a few cells that
express MSC markers alone. Only these few cells could
therefore have been transdifferentiated into neurons
under these conditions. Ideally, however, the cells co-
expressing MSC and neural progenitor markers could
also have been differentiated into neurons with this con-
dition, which is not the case here. Further experiments
needs to be carried out to confirm this.
We next exposed both the hUCB-MSC SCB4 and
hUCB-MSC SCB10 and the RCB 2080 cell line to simple
neuronal differentiation conditions for 5 days (Figure 7A).
We observed a very significantly high percentage (30.08 ±
4.26, P < 0.001) of b-III tubulin-expressing cells in hUCB-
MSC SCB4 and moderately high neuronal differentiation
in hUCB-MSC SCB10 (9.37 ± 1.84), compared with the
RCB 2080 cell line (1.22 ± 0.61; Figure 7B to 7M, N).
These results further indicate that the RCB 2080 cell line,
which has a typical MSC phenotype, may be transdifferen-
tiating alone as a result of pressure from the combination
of growth factors, whereas the hUCB-MSC SCB4 and
hUCB-MSC SCB10 cells co-expressing MSC and neural
progenitor markers, with inherent neurogenic potential,
appear to easily differentiate into neurons without much
pressure or induction with the combination of growth fac-
tors. Even though hUCB-MSC SCB10 has a higher neuro-
genic potential compared with the RCB 2080 cell line, the
potential is still less compared with hUCB-MSC SCB4.
This clearly shows that there is indeed variation in neuro-
genic potential between different batches of expanded
MSCs.
Discussion
MSCs isolated from UCB and bone marrow are shown to
have an inherent potential to differentiate along the meso-
dermal lineage such as adipogenic, chondrogenic and
osteogenic cells [30,31]. A large literature demonstrates
the potential of hUCB-MSCs to transdifferentiate into
neurons by inducing the cells to cross the germline barrier
and generate an ectodermal specified lineage [24]. The
UCB-MSC-derived neurons can be used for treating neu-
rodegenerative disease and can be easily obtained from
discarded cord blood. Recent reports have also shown,
however, that the percentage of robust rapidly expanding
MSCs obtained from UCB is very low [32,33]. Moreover,
different approaches have been taken for generating neu-
rons from UCB-MSCs. Jang and colleagues have demon-
strated that treating MSCs with b-mercaptoethanol and
retinoic acid resulted in a very drastic difference in cellular
morphology of MSCs from a fibroblastic to a spindle-
shaped elongated process resembling the neuronal pheno-
type [19]. Other studies have shown that the hUCB-MSCs
need exposure to four-step treatment with a combination
of growth factors for transdifferentiation into neurons
[24]. These results together therefore indicate that there
appears to be a large difference in the neurogenic potential
of hUCB-MSCs which needs to be properly addressed.
Our results have shown a lot of variation among the
hUCB-MSCs obtained with respect to their neurogenic
potential even though all of them express MSC surface
markers.
The variation in neurogenic potential of the MSCs
obtained seems to originate from the stage of UCB isola-
tion; that is, the gestational period and body weight of
the baby. Our preliminary observations have shown a
direct correlation between the weight of the baby and the
gestation period with respect to MSC yield (Table S1 in
Additional file 1). The majority of UCB that gave a high
yield of MSCs and had very high neuronal differentiation
potential (hUCB-MSC SCB4) originated from babies with
a higher mean body weight and a decreased gestation
period. Previous reports have also shown a high yield of
MSCs from babies with similar clinical parameters
[28,29]. Although this observation is preliminary, it
shows a positive correlation and needs to be investigated
further.
Another interesting observation was the expression of
pluripotent stem cell markers in MNCs directly isolated
from cord blood. These cells had a consistent expression
of Oct4, a master regulator of pluripotency [34]. Oct4 has
been previously reported to be involved in maintenance of
stemness and multipotency of hUCB-MSCs [35] and also
Divya et al. Stem Cell Research & Therapy 2012, 3:57
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Figure 6 Neuronal differentiation of human UCB-MSCs in four-step neuronal induction medium. (A) Schematic of four-step neuronal
induction condition for human umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) differentiation. (B) to (E) Differentiation of the
control RCB 2080 hUCB-MSC cell line with the four-step induction protocol showed transdifferentiation of MSCs to neurons as ascertained by b-III
tubulin immunostaining. (F) to (I) b-III tubulin immunostaining of neurons transdifferentiated from hUCB-MSC SCB4 cells with the four-step
neuronal induction protocol. (J) to (M) Immunostaining of b-III tubulin, a neuronal marker on neurons from hUCB-MSC SCB10 upon four-step
medium treatment. (N) Comparison of percentage of b-III tubulin-positive cells in control RCB 2080 with hUCB-MSC SCB4 and hUCB-MSC SCB10:
~35% b-III tubulin-positive cells were in RCB 2080, whereas ~15% cells in hUCB-MSC SCB4 and 7.4% cells in hUCB-MSC SCB10 were positive for b-III
tubulin - showing a significant difference in pattern of differentiation between the hUCB-MSC cell line RCB 2080 and primary hUCB-MSC SCB4 and
SCB10, indicating that neuronal differentiation potential of primary hUCB-MSCs vary from batch to batch. Data represented as mean ± standard
deviation of triplicates (n = 3) from three different experiments. Scale bar = 100 μm. aFGF, acidic fibroblast growth factor; BF, Bright Feild; bFGF,
basic fibroblast growth factor; bME, beta-mercaptoethanol; DAPI, 4’,6-diamidino-2-phenylindole; IBMX, 3-isobutyl-1-methylxanthine; IMDM, Iscove’s
modified Dulbecco’s medium; NGF, nerve growth factor; PMA, phorbol myristate acetate.
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Figure 7 Neuronal differentiation of human UCB-MSCs in one-step neuronal induction medium. (A) Schematic of one-step neuronal
induction condition for human umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) differentiation. After one-step neuronal
induction, hUCB-MSC SCB4 generated more b-III tubulin+ve neuronal-like cells (F) to (I) compared with the control MSC cell line RCB 2080 (B) to
(E). (J) to (M) b-III tubulin+ve cells observed in the case of hUCB-MSC SCB10 but less compared with hUCB-MSC SCB4, indicating a variation in
differentiation potential among hUCB-MSC samples. (N) Comparison of percentage of b-III tubulin-positive cells in control RCB 2080 with hUCB-
MSC SCB4 and hUCB-MSC SCB10. Only ~4% b-III tubulin-positive cells were in RCB 2080, whereas ~30% cells in hUCB-MSC SCB4 and 9.37% cells
in hUCB-MSC SCB10 were positive for b-III tubulin. Data are expressed as mean ± standard deviation of triplicates (n = 3) from three different
experiments. Scale bar = 100 μm. BF, Bright Field; bFGF, basic fibroblast growth factor; DAPI, 4’,6-diamidino-2-phenylindole; IMDM, Iscove’s
modified Dulbecco’s medium.
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in induction of neurogenesis [36]. Our results showed a
significant expression of ABCG2, Nanog and Sox2, con-
firming the pluripotent nature of hUCB-MNCs. Similar
observation about pluripotent marker expression in UCB-
MSCs had been reported previously by a few groups
[21,37-39]. These results indeed suggest that there exists a
small unique subpopulation of pluripotent progenitors in
cord blood, which upon expansion generates MSCs with
varied neuronal differentiation potential. Overall, our
results have shown clearly that the unexpanded initially
isolated MNCs have a subpopulation of MSC-like cells
that are negative for nestin and positive for pluripotent
stem cell markers Oct4, ABCG2, Nanog and Sox2 in addi-
tion to MSC markers CD105, CD29 and CD44 (Figure 8).
These MNCs upon expansion generate MSCs that are
positive for neuronal progenitor/pluripotency markers
nestin and Oct4, but will be positive or negative for Sox2
and Nanog (high or moderate neurogenic potential; for
example, hUCB-MSC SCB4 and hUCB-MSC SCB10,
respectively; Figure 8) or negative for Oct4, Sox2 and
Nanog (low neurogenic potential; for example, RCB2080
cell line). The progenitors expressing Oct4 may therefore
be responsible for the high neurogenic potential.
Previous reports have also demonstrated the role of
Oct4 in inducing neurogenesis [36,40]. If the number of
the initial Oct4-expressing population is high then these
cells may be preferentially expanded and will generate
MSCs with high neurogenic potential, which can be
very easily differentiated into neurons with minimal
exposure to neurogenic factors (neurobasal medium
with 1% FBS and FGF-2). On the contrary, if the initial
Oct4-expressing population is low then the expanded
Figure 8 Schematic showing the heterogeneity of mesenchymal population obtained from human umbilical cord blood. Human
umbilical cord blood-derived mononuclear cells (hUCB-MNCs) consist of a heterogeneous pluripotent population of cells with varying
neurogenic potential. Upon expansion, the number of cells with inherent neurogenic potential may increase in some cases, which generates
more neuronal differentiation instantaneously, while in other cases cells with less neurogenic potential are expanded, which requires extensive
treatment with a combination of multiple growth factors to achieve neuronal differentiation. aFGF, acidic fibroblast growth factor; bFGF, basic
fibroblast growth factor; bME, beta-mercaptoethanol; IBMX, 3-isobutyl-1-methylxanthine; IMDM, Iscove’s modified Dulbecco’s medium; MSC,
mesenchymal stem cell; NGF, nerve growth factor; PMA, phorbol myristate acetate; RA, retinoic acid.
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MSCs will have very low number of cells with neuro-
genic potential. These MSCs would then require exten-
sive exposure to a combination of growth factors to
transdifferentiate the MSCs into neurons. This differ-
ence may be the reason why the RCB 2080 immorta-
lized MSC line required extensive exposure to different
combination of growth factors for neural differentiation,
since this cell line was clonally generated from immorta-
lized MSCs that lack the pluripotent population.
Conclusion
Our results suggest that the expanded UCB-derived
MSCs harbor a small unique population of cells that
express pluripotent stem cell markers along with MSC
markers and possess an inherent neurogenic potential.
These latter pluripotent progenitors generate cells
expressing neural progenitor markers and are responsi-
ble for the instantaneous neuronal differentiation upon
exposure to regular neuronal differentiation conditions.
We have also shown that the percentage of cells expres-
sing neural progenitor markers may vary from batch to
batch and the batches that have progenitors expressing
MSC markers alone require extensive exposure to a
combination of growth factors to transdifferentiate the
MSCs into neurons. Our findings therefore form the
basis for developing better neuronal differentiation pro-
tocols from MSCs, which can be used for therapeutic
applications.
Additional material
Additional file 1: Table S1 presenting characteristics of UCB
samples that generated MSCs.
Addition file 2: Figure S1 showing immunostaining of embryonic
day 14 mouse cortical neuronal culture as a positive control for
Nestin, Sox2 and Musashi antibodies, which confirms the specificity
of antibodies used in our study.
Additional file 3: Figure S2 showing immunostaining of hUCB-MSCs
with secondary antibody alone, which shows that there is no
background or nonspecific staining.
Additional file 4: Table S2 presenting primer sequences and PCR
conditions used for RT-PCR analysis.
Additional file 5: Figure S3 showing co-localization of neural stem
cell (NSC) and MSC markers in hUCB-MSC SCB10. (A) to (F) CD29 and
CD44 co-localization with NSC marker Musashi was comparably low in
this batch of cells. (G) to (L) At the same time, hUCB-MSC SCB10 showed
expression of Sox2 along with MSC markers CD29 and CD44, even
though the number of Sox2-positive cells was low.
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